Inclusion Criteria:  Males or females, aged ≥ 50 years and ≤ 89 years. An Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA-letter score between ≤ 78 and ≥ 40 in the study eye at Screening. Diagnosis of choroidal neovascularization (CNV) secondary to age-related macular degeneration in the study eye previously treated with anti-VEGF. Participants must have demonstrated a meaningful response to anti-VEGF therapy at study entry. Willing and able to provide written, signed informed consent for this study. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye.  Exclusion Criteria:  CNV or macular edema in the study eye secondary to any causes other than AMD. Subfoveal fibrosis or atrophy in study eye. Any condition in the investigator's opinion that could limit visual acuity improvement in the study eye. Active or history of retinal detachment or retinal tear in the study eye. Advanced glaucoma in the study eye. Prior treatment with gene therapy. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months.